continuous manufacturing of pharmaceuticals
Continuous Manufacturing of Pharmaceuticals: How to Assess Process Fit, PAT, Cost, and Readiness
Start with the decision: is continuous processing a plausible fit?
Continuous manufacturing of pharmaceuticals is a process-design decision, not an equipment decision. You need to determine whether material flow, residence-time behavior, measurement access, control actions, validation evidence, workforce capability, and operating economics fit the product and the intended manufacturing context. A process can appear technically continuous while still lacking the traceability, diversion logic, measurement coverage, or quality-system evidence needed for a defensible implementation.
The useful question is therefore not whether continuous processing is generally more efficient than batch production. The useful question is whether your process can produce material with a defined and controlled relationship between input, process state, downstream response, and output. That assessment should also show where a batch, continuous, or hybrid arrangement leaves unresolved technical questions.
A practical assessment follows the material rather than starting with a technology category. Begin with how raw materials enter and move through the process. Then examine residence-time distribution, process analytical technology, control and diversion decisions, validation, staffing, cost, and regulatory engagement. Continuous manufacturing can use real-time monitoring and control data to support a state of control, but that outcome depends on the complete system design and control strategy rather than on a PAT instrument alone.
Use the rest of this guide to build a technical brief. The result should be a set of questions and evidence requirements for your process, not a general declaration that the process is ready.
Define continuous manufacturing by how material moves
Continuous manufacturing continuously feeds raw materials into integrated unit operations and continuously removes finished product. Material moves through the process as an ongoing stream, while the process design and control strategy determine how that stream is observed, managed, and divided into traceable portions.
Batch manufacturing processes materials through discrete steps and discharges them as a defined lot. Material is loaded, processed, held between operations when applicable, and released from the operation as a defined quantity. The contrast is therefore about the pattern of material movement and decision-making, not simply whether an individual machine operates without interruption.
A continuous process still needs a practical definition of a batch, segment, or collection period for traceability, release, and recall decisions. Ongoing flow does not remove the need to identify which material was made under which process conditions. A control strategy must connect material identity with process data, quality measurements, disturbances, and any diversion decisions.
For your assessment, write down how the process defines its material units and how those units are tracked from input to output. If the proposed design cannot explain that relationship clearly, the process-fit question remains open.
Recognize the practical forms a continuous system can take
Continuous pharmaceutical systems can combine fully continuous operations with physically discrete material segments. A line may therefore contain ongoing flow in one operation, tracked or separated material units in another, and interfaces where material is transferred, sampled, held, or diverted. Treating every continuous system as one uninterrupted stream can hide important design questions about mixing, residence time, tracking, and transition material.
Representative continuous operations include gravimetric feeding, continuous blending, continuous granulation, continuous or semi-continuous drying, continuous-feed compression, and continuous or semi-continuous coating. The appropriate sequence depends on the dosage form, materials, process objectives, and unit-operation design.
Continuous powder blending requires accurate feed-rate control of dry components because powder movement and blending are more difficult than continuous blending of liquids. That distinction makes feeder behavior and mass-flow response part of the process-fit assessment, rather than a detail to address after the line has been selected.
Pharma 4.0 integrates digital technologies and business transformation across GxP-regulated, manufacturing, supply-chain, and business processes. For a continuous line, that broader context matters because process data, quality records, engineering systems, production decisions, and regulatory documentation must support a consistent operating model. A sensor may generate data, but the manufacturing system must determine how that data becomes an authorized process action or quality decision.

Follow material through residence time and traceability
Material traceability is a central design requirement because material entering a continuous process does not necessarily reach every downstream point at the same time. A continuous manufacturing control strategy must address material traceability over time. Residence-time-distribution models can predict material propagation through unit operations and support traceability, including decisions about removing non-conforming material from finished product.
Your process description should show where material enters, how it moves, where it is measured, and how a process event is mapped to the affected output. This path should be understandable to process, quality, engineering, and operations teams.
Residence-time-distribution models can predict material propagation, but their predictions may become less accurate when process setup or material changes exceed the model-development conditions. Model coverage therefore needs to match the operating range that matters for the proposed process. Changes in feed rate, equipment configuration, material properties, or other relevant conditions should be treated as possible changes to model applicability rather than as harmless substitutions.
Use these questions to examine the flow path:
- How is each material feed measured and controlled, and how does a feed-rate change propagate downstream?
- Which residence-time conditions have been characterized for the planned operating range?
- How are start-up, pauses, disturbances, and shutdowns represented in material tracking?
- Where are samples taken to monitor the process?
- Which changes to equipment or material properties would require a new model assessment?
Those dependencies belong in the initial process brief.

Connect PAT measurements to decisions, not dashboards
Process analytical technology is useful when its measurement answers a defined process or quality question. PAT measurements can confirm process operation, verify models, inform divert-to-waste decisions, and support feedback control during continuous-process development. PAT tools—including in-line, online, and at-line monitoring, soft sensors, and process models—can collect real-time data about process dynamics and material quality.
For each proposed measurement, identify the decision it supports. The decision may concern a process adjustment, a material boundary, a model check, a quality attribute, or a response to a disturbance. A dashboard that displays data without a defined decision path does not by itself establish process control.
Spectroscopic PAT can provide direct, chemically specific in-process measurements of product attributes at key control points. PAT can determine final critical quality attributes directly or provide input to models that also use process parameters and material attributes. The measurement may therefore be a direct observation, an input to a model, or part of a larger control strategy; the intended role should be stated before method development begins.
Real-time monitoring and control data can support a state of control for every batch in continuous manufacturing. That support depends on the quality of the measurement, the interpretation model, the process response, and the rules that connect data to action.
Define the following before treating a measurement as operationally meaningful:
- the attribute or process variable being measured;
- the reference method and acceptable relationship between reference and PAT results;
- the conditions under which the model is applicable;
- the action, investigation, or diversion decision triggered by a result; and
- the records needed to explain the decision afterward.
The measurement system and the decision system should be designed together.

Compare the potential gains with the integration burden
Continuous manufacturing can use a smaller footprint than batch processing and may require lower capital investment in some configurations. It often reduces operation steps, which can support higher efficiency and less human error. Commercial continuous process units can also be used during drug development, potentially avoiding process scale-up between development and commercial manufacturing.
Continuous manufacturing can change production output without increasing equipment size and may allow development knowledge to be generated at the intended commercial scale. These are potential design and operating advantages, not guaranteed outcomes. Your comparison should state which cost category, production condition, and process evidence support each expected gain.
High upfront investment and integration complexity may restrain adoption, particularly where existing batch facilities are fully depreciated. Equipment, PAT, control systems, data handling, material tracking, and quality records must work as a coordinated system. A smaller footprint does not automatically mean a lower project cost when installation, integration, validation, training, and changes to the existing facility are included.
Scale-up is a separate question from whether a unit operation works in a development setting. When a continuous manufacturing process is scaled up, assess scale-up risks and the original control strategy at the new scale, modifying the strategy where needed. Your comparison should therefore include the process scale, intended output, material behavior, measurement coverage, control response, and evidence required at that scale.
Put adoption and affected teams in context
Pharmaceutical continuous manufacturing remains an emerging operating model rather than a routine replacement for batch production. Adoption has been slow overall, especially among generic-medicine manufacturers, because economic, regulatory, and workforce-capacity challenges affect implementation. Limited practical experience can also contribute to risk-avoiding decisions and slower adoption.
The affected teams extend beyond process development. Process engineers define unit operations and flow behavior; PAT and analytical teams define measurements and models; quality teams connect data to material disposition; operations teams manage the line; engineering teams maintain equipment and interfaces; regulatory teams prepare the applicable submission; and workforce leaders address training and operating capability. Regulators and inspectors also encounter the evidence package and control strategy.
A cited market analysis reported that, in May 2026, 17 drugs had been approved using continuous manufacturing and 72 continuous manufacturing technologies had been accepted into the U.S. FDA Emerging Technology Program. The figures measure U.S. regulatory activity and accepted technologies, not the number of facilities operating continuous lines worldwide.
The same cited market analysis stated that only a little more than 15 drug products were being manufactured using continuous manufacturing as of mid-2025, despite strong industry interest. That figure measures products in manufacture at a stated time, whereas the May 2026 figures measure approvals and program acceptances. Treat the measures as context for adoption, not as a universal prevalence rate.
A project in Singapore, North America, South America, or Europe still needs a jurisdiction-specific regulatory and quality review. The applicable agency, submission pathway, facility history, workforce experience, and quality system can change the implementation path. The U.S. market figures above should not be used to infer adoption, approval status, or regulatory expectations for another region.

Estimate cost by separating installation from operating economics
Continuous manufacturing costs should be separated into installation, integration, validation, staffing, maintenance, operating inputs, campaign utilization, and product-specific development. Continuous lines may cost more to install but may offer a lower cost per unit at high volumes. Increased processing speed and control can lower production costs, especially for high-volume production, but the economic result depends on the process and operating conditions.
Short continuous-production campaigns deserve particular attention because start-up and shutdown time can be significant and can affect economic results. A line that looks attractive at steady state may have a different result when transition material, planned stops, cleaning, maintenance, and low campaign utilization are included.
A cited engineering-based analysis of a representative oral solid-dose product at a high-volume scale of 2,000 tons of tablets per year used estimated new-facility batch-processing operating costs of $226 million and capital costs of $346 million. Those figures describe the batch-processing assumptions in that analysis; they are not a price for a continuous line or a universal estimate for pharmaceutical manufacturing.
A cited commercial analysis reported that eliminating hold times and reducing manual intervention could lower operational costs by up to 30%. That figure belongs to the analysis’s stated assumptions and should not be transferred to your process without checking the hold-time profile, labor model, process design, and operating scale.
Build a cost comparison with at least these categories:
- installed equipment and facility changes;
- PAT, control, data, and integration work;
- process development, model development, validation, and regulatory submissions;
- staffing, training, maintenance, and specialist support;
- start-up, shutdown, diversion, waste, and campaign effects; and
- expected output, utilization, and cost per usable unit.
Hybrid approaches can help manufacturers offset high initial cost, increase output, and gain experience with continuous unit processes. Include a hybrid case when a full conversion would make the economic comparison depend on assumptions you cannot yet support.

Turn process fit into an evidence-gathering brief
A process-fit brief should make each design assumption testable. Start with the product, materials, intended output, operating range, unit operations, quality attributes, and process parameters. Then connect each measurement to the decision it is expected to support.
Use the brief to compare continuous, batch, and hybrid options against the same evidence. A suitable control strategy is needed to track materials accurately through continuous manufacturing and support drug product quality.
Organize the brief around these questions:
- Material behavior: Which material properties affect feeding, mixing, transport, residence time, or downstream quality?
- Flow and traceability: What does the residence-time-distribution model cover, and how will material be traced through each unit operation?
- Measurement: Which critical quality attributes or process variables require direct, chemically specific, in-line, online, at-line, or laboratory measurement?
- Decision logic: What result changes a process setting, starts an investigation, triggers diversion, or supports disposition?
- Model coverage: Which feedstock, temperature, pressure, concentration, equipment, and operating conditions are represented in the model or method?
- Data continuity: How will incoming-material, in-process, finished-product, process-parameter, and endpoint data be connected?
- Scale: Which risks arise when the process moves to the intended production scale, and which control-strategy elements need reassessment?
- Evidence: What development, validation, quality-system, and regulatory records must exist before the proposed operation is used for its intended purpose?
The brief should expose unanswered questions. It should not hide them behind a general claim that real-time data will solve process variability.
If the project uses a traditional process-validation scheme under the cited EMA framework, the number of production-scale batches depends on process variability, process or product complexity, and manufacturer experience, but would usually be a minimum of 3 consecutive batches. That figure applies to the cited EMA scheme and its stated conditions; your applicable jurisdiction and validation approach may differ. Record the intended validation route and the reasons supporting it in the fit brief.
Use hybrid implementation when a full conversion is not the first move
Hybrid approaches can introduce continuous manufacturing step by step by combining batch and continuous processes. A hybrid design may let you evaluate a continuous unit process, its measurement needs, its material-tracking behavior, or its operating interface without requiring an immediate end-to-end conversion.
Hybrid approaches can help manufacturers assess continuous-process benefits and progressively transition toward end-to-end continuous manufacturing. They still require a defined control strategy, clear interfaces between batch and continuous operations, and an evidence plan for the material moving across those interfaces.
Use a hybrid case when the evidence is stronger for a particular unit operation than for the complete process. Compare the hybrid design with the batch baseline and the full-continuous design using the same criteria: flow and traceability, PAT access, control response, transition handling, validation, staffing, installation, and cost. If scale-up changes the material behavior or control strategy, assess those risks before treating the staged path as evidence for the larger system.
Build the validation and quality-system path with the process design
A continuous process-verification plan should collect relevant data on incoming materials, in-process material, and finished products. The data should include critical quality attribute and critical process parameter trends, along with relevant attributes, parameters, and endpoints. Pharmaceutical quality-system expectations apply to both batch and continuous manufacturing and should follow the pertinent ICH guidelines.
Your evidence plan should link those records to material identity, process state, deviations, investigations, corrective actions, and disposition decisions. The exact records and approval path depend on the applicable quality system and jurisdiction, but the relationship between process data and quality decisions should be explicit.
Regional process-validation requirements are similar for continuous and batch manufacturing processes, subject to the applicable jurisdiction, but the submission must still explain why the selected approach is appropriate for the product and process.
Treat regulatory engagement as part of process design. Prepare the material-flow definition, control strategy, PAT method, model applicability, diversion logic, validation rationale, and quality-system records as one connected package. A change to one part can change the evidence required in another.
Seek qualified evaluation before a consequential process decision
Startup, restart, pause, stop, and shutdown require defined procedures because transition material may not meet specifications. A continuous manufacturing control strategy should define these procedures; during startup or restart, material is diverted until it meets predefined acceptance criteria for collection.
A continuous manufacturing system must also define how disturbances are detected and how affected material is isolated. Do not approve a consequential process change while the team cannot explain what happens to material produced during a transition or disturbance.
A continuous process should establish criteria for starting and ending a material-diversion period. When traceability, process monitoring, and diversion strategies are well established, non-conforming material can be diverted from the rest of the batch.
Pause the decision and bring together process, quality, engineering, validation, regulatory, and operations specialists when any of these boundaries remains unclear:
- the affected material cannot be identified;
- the disturbance cannot be detected or bounded;
- the start or end of diversion has no predefined criterion;
- the measurement cannot support the proposed action; or
- the proposed change would alter the process, validation evidence, or regulatory filing.
Proper documentation and validation are needed to support advanced manufacturing technologies at a manufacturing site. A cited study found that 90% of respondents considered advanced manufacturing technology extremely beneficial for production efficiency, but perceived benefit does not replace the documentation, training, control, and validation needed for a specific site.
Do not use PAT, a process model, or an instrument alone as proof of product quality, process control, validation, compliance, or regulatory acceptance. Escalate immediately when a manufacturing, quality, safety, patient-risk, or regulatory issue could be affected by an unresolved process decision.
Prepare the next technical conversation
A useful next conversation starts with a compact process brief: describe the stream, concentration range, operating temperature and pressure, presence of solids, required accuracy, measurement objectives, representative samples, expected operating range, control questions, and validation context. The brief should make clear whether you are exploring a feasibility question, a measurement method, a model, or an implementation path.
We offer to test the OrionIR® on customer process samples when it makes sense. We require the stream composition, concentration range, accuracy, temperature, pressure, and presence of solids to start the testing process. We build calibration models for chemistry and integrate them into instrument software to provide real-time concentration readouts.
Our chemometric calibration process involves defining the measurement, designing the calibration set, collecting references, building and cross-validating the model, validating it on held-out batches, and deploying and monitoring the model. We document preprocessing and validation so the model is transferable and auditable, and we provide ongoing chemometric-model support, including revalidation as feedstock, temperature, or product specifications change.
A qualified process, quality, validation, engineering, and regulatory review determines whether a particular process or measurement approach is suitable for its intended use; a scoped technical discussion can help you frame the questions and evidence needed for that review.
What should you clarify before evaluating continuous pharmaceutical manufacturing?
Is continuous manufacturing of pharmaceuticals suitable for every product or facility?
No. Suitability depends on material behavior, feed control, residence-time distribution, measurement access, control and diversion logic, facility integration, workforce capability, validation evidence, operating economics, and the applicable regulatory framework. A process-specific assessment is required before deciding whether batch, continuous, or hybrid production is appropriate.
Can PAT or an inline spectrometer alone demonstrate that a process is ready for pharmaceutical production?
No. PAT can provide process and quality information, support models, and inform control or diversion decisions, but it does not by itself establish process control, product quality, validation, compliance, or regulatory acceptance. The measurement must be supported by validated methods, applicable calibration models, defined decision rules, data integrity controls, and a complete quality and control strategy.
What information should a team prepare before evaluating a continuous manufacturing project?
Prepare the product and material description, stream composition, concentration range, operating temperature and pressure, solids content, required measurement accuracy, unit operations, intended output, operating range, critical quality attributes, critical process parameters, residence-time assumptions, sampling and diversion points, validation context, and applicable jurisdiction. This brief helps specialists evaluate process fit and identify evidence gaps without assuming that the project is ready.
How should the cost of a continuous pharmaceutical process be estimated when no universal price applies?
Separate installed equipment and facility changes from PAT, automation and data integration, process and model development, validation, regulatory work, staffing, training, maintenance, transition material, diversion, campaign utilization, and ongoing operation. Compare those costs with expected usable output and utilization against batch and hybrid alternatives. Installation may cost more while unit economics may improve at high volume, but the result depends on the specific process, facility, scale, campaign pattern, and evidence requirements.